探索癌症干细胞和瘤微环境之间的动态相互作用:对新型治疗策略的含义
Yan-Ruide Li1, Ying Fang2, Zibai Lyu2
1Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA. charlie.li@ucla.edu.
癌症干细胞 (CSCs) 通过逃避免疫反应来驱动瘤生长和转移. 针对CSC及其微环境 (TME) 对于克服治疗耐药性和改善癌症治疗结果至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 癌症干细胞 (CSCs) 是瘤发育,生长,转移和治疗抵抗的关键驱动因素.
- 中枢癌细胞积极诱导免疫逃避,显著损害抗癌免疫反应.
- 瘤微环境 (TME) 支持CSC的生存和自我更新,而CSC则促进免疫抑制的TME.
研究的目的:
- 审查CSC针对免疫逃避和治疗耐药性的策略.
- 检查CSC与TME之间的互动关系.
- 探索针对CSC和TME的新型治疗策略.
主要方法:
- 对CSC,TME和癌症免疫学研究的文献综述.
- 对CSC-TME通信通道的分析.
- 新兴治疗方法的概述.
主要成果:
- CSC使用复杂的机制来逃避免疫监控.
- CSC-TME轴促进了一个免疫抑制瘤环境.
- 针对CSC和调节TME是有前途的治疗途径.
结论:
- 了解CSC-TME相互作用对于开发有效的癌症治疗至关重要.
- 针对CSC和TME的新疗法有可能改善临床结果.
- 对于这些策略的临床转化,需要进一步的研究.
更多相关视频
09:18Heteromulticellular Stromal Cells in Scaffold-free 3D Cultures of Epithelial Cancer Cells to Drive Invasion
Published on: April 4, 2025
09:52A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication
Published on: September 20, 2016
相关概念视频
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
The Tumor Microenvironment
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
